Endocrinology

>

Latest News

FDA approves teplizumab for delay of type 1 diabetes in patients 8 years and up
FDA approves teplizumab for delay of type 1 diabetes in patients 8 years and up

November 18th 2022

The US FDA announced the approval of teplizumab (Tzield), which is administered through IV infusion once daily for 14 consecutive days, for delaying the onset of stage 3 type 1 diabetes in adults and pediatric patients 8 years and older who currently have stage 2 type 1 diabetes.

Study finds children, young adults with down syndrome more likely to develop diabetes
Study finds children, young adults with down syndrome more likely to develop diabetes

October 17th 2022

 In gestational diabetes, tighter glycemic targets could influence outcomes for mother and child
In gestational diabetes, tighter glycemic targets could influence outcomes for mother and child

September 23rd 2022

Diabetes not associated with breastfeeding ability
Diabetes not associated with breastfeeding ability

September 9th 2022

Podcasts

More News

© 2023 MJH Life Sciences

All rights reserved.